

Jointly led by Atinum Investment and KB Investment
Cumulative funding reaches KRW 62.2 billion
Expanding domestic and overseas supply of AI robotic endoscopes
Global medical robotics startup MedInTech has raised KRW 33.8 billion in a Series C funding round. Building on its robotic control technology developed for diagnostic endoscopes, the company plans to expand into the market for medical robots used in treatment and surgery. Its cumulative funding now stands at approximately KRW 62.2 billion, and MedInTech plans to close the Series C round with additional fundraising by the end of the year.
View original image
On the 17th, a MedInTech representative said the investment was jointly led by Atinum Investment and KB Investment. Existing investors Smilegate Investment, SL Investment, ICF (Nextrance), and Wooshin Venture Investment participated in the follow-on round, while K2 Investment Partners joined as a new investor.
Founded in 2020, MedInTech has developed medical devices that combine robotic precision-control technology and artificial intelligence (AI) for gastrointestinal endoscopy. Its flagship product, INTION S, uses a motor to control movement, unlike conventional systems in which medical staff manually pull a wire to steer the endoscope. It also uses AI to assist with some aspects of examinations, including controlling the endoscope’s direction and tracking lesions.
According to MedInTech, a clinical trial involving 178 adults at Seoul National University Hospital found that the device was not inferior to conventional mechanical endoscopes in key aspects of maneuverability. The trial also confirmed that it reduced physical fatigue among medical staff. The findings were published in the international journal Scientific Reports.
In South Korea, the company signed a nationwide distribution agreement with DK Healthcare and supplied its products to the National Fire Agency Hospital and Ajou University Hospital, among others. It has also secured initial sales in three overseas markets: Thailand, the Philippines, and Mongolia. The company has commercialized Intion DeepEye, AI software that detects and classifies abnormal areas in stomach and colon endoscopy images.
The funding will be used to expand its AI robotic endoscopy product line and develop surgical robots. The company plans to recruit research and development (R&D) staff, develop prototypes, obtain domestic and international regulatory approvals, and establish mass-production capabilities. In particular, in conjunction with a KRW 22.8 billion cross-ministerial advanced medical device R&D program for which it was selected last April, MedInTech will work to advance its autonomous steering technology and develop miniaturized, multi-jointed therapeutic instruments.
Hot Picks Today
“Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?” … ‘Dreamland’ Shunned by Kids and Foreign Tourists
Lee Chiwon, CEO of MedInTech, said, “This Series C funding is an important opportunity to prepare for our next stage of growth, building on the robotic endoscopy technology we have developed and our commercialization achievements. We will expand the supply of AI robotic endoscopes in South Korea and overseas, advance our autonomous steering and precision-control technologies, and build a next-generation medical robotics platform spanning diagnosis, treatment, and surgery.”
This content was produced with the assistance of AI translation services.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
Source link